ADMA Biologics
ADMA
67 hedge funds and large institutions have $136M invested in ADMA Biologics in 2019 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 34 increasing their positions, 7 reducing their positions, and 3 closing their positions.
1,416% more capital inflows, than outflows
Capital inflows: $60.5M | Capital outflows: $3.99M
433% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 3
386% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 7
137% more call options, than puts
Call options by funds: $303K | Put options by funds: $128K
20% more funds holding
Funds holding: 56 → 67 (+11)
10.97% more ownership
Funds ownership: 48.1% → 59.06% (+11%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Perceptive Advisors
New York
|
+$22.1M |
| 2 |
Schonfeld Strategic Advisors
New York
|
+$8.57M |
| 3 |
CCM
Consonance Capital Management
New York
|
+$4.93M |
| 4 |
BlackRock
New York
|
+$4.06M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.47M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
-$3.23M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$207K |
| 3 |
Barclays
London,
United Kingdom
|
-$167K |
| 4 |
DG
Delek Group
Herzliya,
Israel
|
-$132K |
| 5 |
MWVC
Morgens Waterfall Vintiadis & Co
New York
|
-$110K |
ADMA Hedge Fund Activity: Q2 2019 in Review
67 of the 4,626 institutional investors tracked by Wall St. Rank reported a position in ADMA Biologics (ADMA) for Q2 2019, worth a combined $136M — up 60% from $84.5M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new ADMA positions and 3 closed out — a net gain of 13 holders — while 34 added to existing stakes and 7 trimmed.
The largest buyer was Perceptive Advisors, adding an estimated $22.1M. The largest seller was Broadfin Capital, cutting an estimated $3.23M.
- 67 institutional investors held ADMA Biologics (ADMA) as of Q2 2019, up from 56 in Q1 2019.
- Funds reported $136M of ADMA Biologics stock for Q2 2019, up 60% quarter-over-quarter.
- 16 funds opened new ADMA Biologics positions in Q2 2019 and 3 closed out, a net change of +13 holders.
- The largest ADMA Biologics buyer in Q2 2019 was Perceptive Advisors, an estimated $22.1M added.
- The largest ADMA Biologics seller in Q2 2019 was Broadfin Capital, an estimated $3.23M sold.
Based on aggregated 13F filings for Q2 2019.